Panelists discuss how patients currently on injectable androgen deprivation therapy can transition to oral options through an overlap period, and how stated drug interactions with androgen receptor pathway inhibitors have not been clinically significant in practice.
Panelists discuss how shared decision-making allows patients to test-drive oral androgen deprivation therapy options, providing flexibility for those concerned about quality-of-life impact or performance status, enabling them to start or stop treatment as needed.
Panelists discuss how patient preference plays a significant role in androgen deprivation therapy selection, with most patients preferring oral agents that offer rapid onset and quick testosterone recovery when treatment is stopped.
Panelists discuss how clinicians can confidently adapt to newer androgen deprivation therapy options like relugolix in combination therapies despite limited prospective data, emphasizing that oral agents simplify patient visits and provide equivalent testosterone suppression.
Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being standard of care rather than ADT monotherapy in most cases.
Panelists discuss how patient adherence to oral androgen deprivation therapy has been reliable in both clinical trials and practice, with the convenience of daily pills and portability during travel contributing to good compliance rates.
Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular risk profile, and the potential for rapid testosterone recovery.
Panelists discuss how oral androgen deprivation therapy options like relugolix fit into current treatment strategies across multiple patient categories, offering advantages in rapid onset, quick recovery, and convenience, particularly for patients requiring short-term treatment or those with cardiovascular risk factors.
Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more rapid onset, faster recovery, and avoidance of testosterone flare.
Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.
Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.
Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to control disease progression and improve patient survival.
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
